Sign in
Not yet recruitingPhase 3

Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease

Key facts

Who runs it
Chinese PLA General Hospital
Where
China3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
146 people, planned
Started
1 Aug 2026
Expected to end
31 Dec 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Lenalidomide
  • Placebo
Record updated
22 July 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Adults aged 18 to 75 years at the time of screening
  • Diagnosis of IgG4-related disease according to the 2019 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria
  • Patients with IgG4-related disease who have achieved sustained clinical remission following glucocorticoid therapy
  • No documented IgG4-related disease relapse within the previous 12 months before screening
  • IgG4-related disease Responder Index (IgG4-RD RI) score of 0 at screening
  • Receiving stable low-dose glucocorticoid therapy with prednisone-equivalent dose ≤7.5 mg/day for at least 6 months before randomization
  • Ability to provide written informed consent and comply with study procedures

Who cannot take part

  • Previous treatment with lenalidomide or known hypersensitivity to lenalidomide or related compounds
  • Requirement for prohibited concomitant medications during the study period
  • Significant hepatic or renal dysfunction that may affect study participation or drug safety evaluation
  • Active IgG4-related disease requiring induction therapy or escalation of immunosuppressive treatment at screening
  • Significant uncontrolled infection or active severe infection
  • History of thromboembolic events or conditions associated with unacceptable thrombotic risk according to investigator assessment
  • Malignancy or other severe medical conditions that may interfere with study participation or outcome assessment
  • Any condition that, in the investigator's opinion, may compromise participant safety or affect the reliability of study results
  • Clinically significant hematologic abnormalities, including severe neutropenia or thrombocytopenia
  • Pregnancy, breastfeeding, or unwillingness to use effective contraception when applicable

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Immunoglobulin G4-related disease (IgG4-RD) is a chronic immune-mediated disorder characterized by inflammation, fibrosis, and involvement of multiple organs. Although glucocorticoids can effectively induce remission, many patients experience disease relapse after glucocorticoid tapering or discontinuation, and long-term glucocorticoid exposure may cause significant adverse effects. Therefore, new maintenance treatment strategies are needed to reduce relapse risk and minimize glucocorticoid-related toxicity.

Read full original descriptionShow less

This study is designed to evaluate the efficacy and safety of lenalidomide as a maintenance therapy in patients with stable IgG4-RD. This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial.

Eligible participants will be adults with IgG4-RD who meet the 2019 ACR/EULAR IgG4-RD classification criteria and are in a stable disease state. Participants will be randomly assigned in a 1:1 ratio to receive either lenalidomide or matching placebo for 52 weeks. All participants will receive standardized glucocorticoid tapering according to the study protocol.

The primary objective of this study is to determine whether lenalidomide can reduce the risk of IgG4-RD relapse compared with placebo. The primary outcome is the proportion of participants experiencing disease relapse within 52 weeks after randomization.

Secondary objectives include evaluation of time to relapse, maintenance of remission, changes in disease activity, quality of life, and safety outcomes. Exploratory assessments will investigate changes in immunological biomarkers, peripheral blood immune profiles, transcriptomic characteristics, and gut microbiota.

This study aims to provide clinical evidence for a new maintenance treatment approach for patients with IgG4-RD and potentially reduce disease recurrence and glucocorticoid exposure.

The 2 groups in the trial

  • Lenalidomide ArmTreatment being tested

    Participants will receive lenalidomide 5 mg orally once daily for 52 weeks as maintenance therapy. All participants will undergo standardized glucocorticoid tapering according to the study protocol during the initial treatment period. Lenalidomide will be administered in addition to background glucocorticoid management.

    Treatment: Lenalidomide

  • Placebo ArmPlacebo, for comparison

    Participants will receive matching placebo orally once daily for 52 weeks as maintenance therapy. All participants will undergo standardized glucocorticoid tapering according to the study protocol during the initial treatment period. The placebo will be identical in appearance, packaging, labeling, and administration procedures to lenalidomide.

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III Multicenter Randomized Double-Blind Placebo-Controlled Study Evaluating the Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
Criteria questions
Built from NCT07719543, who can take part
Record updated
22 July 2026